Publications & News | SILLAJEN

Publications & News

Targeting, Attacking, and Eradicating Cancers®

Publications & News

게시판

Total 28. ˙ 2/3 Page

18 SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's Pexa-Vec Oncolytic Immunotherapy 2017-08-17
17 SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 2017-07-25
16 SillaJen teams up with Regeneron to combat kidney cancer 2017-05-10
15 Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer 2017-05-08
14 Enrollment of the First European Patient in Multinational Phase 3 Trial 2017-04-24
13 Issuance of Two Australian Patents 2017-03-02
12 SillaJen IR Letter (2017.01) 2017-01-03
11 SillaJen to use IPO proceeds to fund clinical trial of liver cancer drug in 11 countries 2016-11-14
10 SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec 2016-05-17
9 SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 2016-03-29